M&S Technologies, Inc. recently released Version 2 of its Clinical Trial Suite (CTS), which allows pharmaceutical companies to gain greater information and control in trials with customized testing protocols designed specifically for them.
According to M&S, CTS is a fully-automated, customizable suite of software modules designed specifically for use in vision-related research and clinical trials. CTS includes a variety of visual acuity and contrast sensitivity algorithms that easily step the user through the eye charts presented and directly respond to user input regarding correct/incorrect results, and each suite can be customized specifically to meet the sponsors' trial needs. The CTS modules also adhere to ANSI and ISO standards, are accepted for use in Phase III endpoint trials, and are peer-reviewed and published by prominent industry professionals.
Click here to read the full press release.